Bristol-Myers Squibb (BMY) to Acquire Turning Point Therapeutics (TPTX) for $76 Per Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
June 3, 2022 6:59 AM EDTAcquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023
Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share
Expected to be Accretive to Non-GAAP Earnings Per Share beginning in 2025
NEW YORK & SAN DIEGO--(BUSINESS... More



